Marinus Pharmaceuticals, Inc. - Special Call Transcript
Greetings. Welcome to Marinus PPD data webcast. (Operator Instructions).
Please note this conference is being recorded. I would now like to turn the conference over to Lisa Caperelli with IR. Thank you. You may begin.
Thank you, Sherry. Good morning, everyone, and thank you for joining this conference call where we will review data from our Magnolia and Amaryllis Phase II clinical studies, evaluating ganaxolone treatment regimens in women with Postpartum Depression.
Participants on today's call are Dr. Scott Braunstein, Executive Chairman of Marinus; and Dr. Lorianne Masuoka, our Chief Medical Officer. Dr. Kimberly McCormick, our Head of Regulatory Affairs; and Edward Smith, our CFO, are also on the line and will be available to answer questions during the Q&A session.
There are slides accompanying today's call in order to access these slides, please log into the webcast that's accessible from the Investor Relations
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |